Scientists undertake multiple strategies to tame Ebola virus

NewsGuard 100/100 Score

The Ebola epidemic in West Africa has pushed the decades-long search for a treatment to a frenetic pace. Somewhere in the virus' deceptively simple structure is a key to taming it. To find that key, scientists are undertaking multiple strategies, some of which are being fast-tracked for human testing, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.

Senior editors Lisa M. Jarvis and Bethany Halford of C&EN note that the Ebola virus is endowed with a mere seven genes that code for eight proteins. Although few in number, the proteins each have many functions, which allow the virus to commandeer nearly 70 proteins from a person it infects. To fight this highly efficient virus, scientists are taking several approaches. They're designing antibodies to prevent the virus from attaching to host cells, and working on small molecules to attack the virus at various stages of its life cycle. They're also starting clinical trials on antiviral drugs that are already approved to treat other kinds of infections.

If developed quickly enough, an effective treatment could curb the current outbreak. It could also potentially spare the world from future epidemics. But as some scientists point out, drugs and vaccines take years to tailor into safe and effective therapies, so it's essential the efforts continue long after this crisis passes.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine